In this study bevacizumab was labeled with 99mTc using p-SCN-Bzl-TCMC as a chelator for non invasive imaging of VEGF receptor in ovarian tumor Sprague Dawley rat and New Zealand rabbit models. High radiochemical purity and stability were observed using 0.4 mL of conjugated TCMC-bevacizumab. In vitro binding studies showed higher uptake of labeled conjugated bevacizumab with high metastatic SKOV-3 ipl cells as compared to poor metastatic SKOV-3. Biodistribution in rat model confirmed higher accumulation of labeled conjugated bevacizumab in the site infected with SKOV-3 ipl cells as compared to SKOV-3. Images of ovarian tumor rabbit model validated its specificity and efficacy as a promising ovarian tumor imaging agent.

中文翻译：

---

使用卵巢癌模型合成 99mTc-p-SCN-Bzl-TCMC-bevacizumab 用于血管内皮生长因子 (VEGF) 受体成像

在这项研究中，贝伐单抗用 99mTc 标记，使用 p-SCN-Bzl-TCMC 作为螯合剂，用于在卵巢肿瘤 Sprague Dawley 大鼠和新西兰兔模型中对 VEGF 受体进行非侵入性成像。使用 0.4 mL 偶联的 TCMC-贝伐单抗观察到高放射化学纯度和稳定性。体外结合研究表明，与低转移性 SKOV-3 细胞相比，高转移性 SKOV-3 ipl 细胞对标记的偶联贝伐单抗的吸收更高。大鼠模型中的生物分布证实，与 SKOV-3 相比，标记的结合贝伐单抗在感染 SKOV-3 ipl 细胞的部位有更高的积累。卵巢肿瘤兔模型的图像验证了其作为有前途的卵巢肿瘤显像剂的特异性和功效。